Cardiothoracic & vascular anesthesia
Mortality and adverse events of extracorporeal haemoadsorption therapy in cardiac surgery: a systematic review and meta-analysis of randomised controlled trials
Pooled result · MortalityResult — go to the resultOdds ratio 1.08 95% CI 0.59–2.01Authors' conclusion
This meta-analysis did not show evidence of clinical benefit for routine use of HA during CPB for cardiac surgery, although clinically relevant benefit or harm cannot be excluded on the currently available evidence.
Study context
- Population
- Adults undergoing cardiac surgery with cardiopulmonary bypass (CPB)
- Participants
- 713 adults · 12 RCTs
- Comparison
- Haemoadsorption (HA) inserted into the CPB circuit vs conventional CPB without HA
- Outcome
- Mortality
Pooled result
As reported in the abstract
Odds ratio
1.08
95% CI 0.59–2.01
P = 0.75
HA vs Conventional CPB
OR 1.08 (95% CI 0.59–2.01); P = 0.75
Further pooled results
| Outcome | Pooled mean difference (95% CI) | P value | |
|---|---|---|---|
| Hospital LOS | 0.21 (−1.89-2.30) | P = 0.82 | |
| ICU LOS | −0.36 (−1.31-0.60) | P = 0.42 | |
| −2−10123Difference (linear scale) |
Requirements for ventilation, cardiovascular support or RRT
- No significant difference
Safety
Adverse events
- No significant difference
Original publication
Mortality and adverse events of extracorporeal haemoadsorption therapy in cardiac surgery: a systematic review and meta-analysis of randomised controlled trials. Br J Anaesth. Published 21 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →